肝硬変治療薬の世界市場 2024-2028

概要

肝硬変治療薬市場は、2023年から2028年にかけて19億4,000万米ドル、予測期間中のCAGRは5.58%で成長すると予測されています。

当レポートでは、肝硬変治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。肝がんの罹患率の増加、医学研究の進歩、製薬企業とヘルスケアプロバイダーとの協力関係の増加などが市場を牽引しています。

本調査では、個別化医療の動向が今後数年間の肝硬変治療薬市場成長を牽引する主要因の1つであると分析しています。また、非侵襲的な治療オプションやデジタルヘルステクノロジーの統合が重視されるようになることで、同市場には大きな需要が見込まれます。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 肝硬変治療薬の世界市場 2018-2022
• タイプセグメント分析 2018-2022
• エンドユーザーセグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：タイプ別

• 市場セグメント
• 比較：タイプ別
• オーラル：市場規模と予測 2023-2028
• 注射：市場規模と予測 2023-2028
• 市場機会：タイプ別

第7章 市場セグメンテーション：エンドユーザー別

• 市場セグメント
• 比較：エンドユーザー別
• 病院：市場規模と予測 2023-2028
• クリニック：市場規模と予測 2023-2028
• 調査および学術機関：市場規模と予測 2023-2028
• 市場機会：エンドユーザー別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• 日本：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Alnylam Pharmaceuticals Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• CSL Ltd.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Gwo Xi Stem Cell Applied Technology
• Johnson and Johnson
• Kezar Life Sciences Inc.
• Merck KGaA
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• Protagonist Therapeutics Inc.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Type
• Exhibits6: Executive Summary - Chart on Market Segmentation by End-user
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global liver cirrhosis therapeutics market 2018 - 2022 ($ billion)
• Exhibits19: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
• Exhibits20: Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Type - Market share 2023-2028 (%)
• Exhibits31: Data Table on Type - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Type
• Exhibits33: Data Table on Comparison by Type
• Exhibits34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibits35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibits36: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Injection - Market size and forecast 2023-2028 ($ billion)
• Exhibits39: Data Table on Injection - Market size and forecast 2023-2028 ($ billion)
• Exhibits40: Chart on Injection - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Injection - Year-over-year growth 2023-2028 (%)
• Exhibits42: Market opportunity by Type ($ billion)
• Exhibits43: Data Table on Market opportunity by Type ($ billion)
• Exhibits44: Chart on End-user - Market share 2023-2028 (%)
• Exhibits45: Data Table on End-user - Market share 2023-2028 (%)
• Exhibits46: Chart on Comparison by End-user
• Exhibits47: Data Table on Comparison by End-user
• Exhibits48: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
• Exhibits49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
• Exhibits50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
• Exhibits51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
• Exhibits52: Chart on Clinics - Market size and forecast 2023-2028 ($ billion)
• Exhibits53: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion)
• Exhibits54: Chart on Clinics - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Clinics - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
• Exhibits57: Data Table on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
• Exhibits58: Chart on Research and academic institutes - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Research and academic institutes - Year-over-year growth 2023-2028 (%)
• Exhibits60: Market opportunity by End-user ($ billion)
• Exhibits61: Data Table on Market opportunity by End-user ($ billion)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibits92: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibits93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibits96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibits97: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits103: Market opportunity By Geographical Landscape ($ billion)
• Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ billion)
• Exhibits105: Impact of drivers and challenges in 2023 and 2028
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: Alnylam Pharmaceuticals Inc. - Overview
• Exhibits112: Alnylam Pharmaceuticals Inc. - Product / Service
• Exhibits113: Alnylam Pharmaceuticals Inc. - Key news
• Exhibits114: Alnylam Pharmaceuticals Inc. - Key offerings
• Exhibits115: Astellas Pharma Inc. - Overview
• Exhibits116: Astellas Pharma Inc. - Product / Service
• Exhibits117: Astellas Pharma Inc. - Key news
• Exhibits118: Astellas Pharma Inc. - Key offerings
• Exhibits119: AstraZeneca Plc - Overview
• Exhibits120: AstraZeneca Plc - Product / Service
• Exhibits121: AstraZeneca Plc - Key news
• Exhibits122: AstraZeneca Plc - Key offerings
• Exhibits123: CSL Ltd. - Overview
• Exhibits124: CSL Ltd. - Business segments
• Exhibits125: CSL Ltd. - Key offerings
• Exhibits126: CSL Ltd. - Segment focus
• Exhibits127: F. Hoffmann La Roche Ltd. - Overview
• Exhibits128: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits129: F. Hoffmann La Roche Ltd. - Key news
• Exhibits130: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits131: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits132: Gilead Sciences Inc. - Overview
• Exhibits133: Gilead Sciences Inc. - Product / Service
• Exhibits134: Gilead Sciences Inc. - Key news
• Exhibits135: Gilead Sciences Inc. - Key offerings
• Exhibits136: GlaxoSmithKline Plc - Overview
• Exhibits137: GlaxoSmithKline Plc - Business segments
• Exhibits138: GlaxoSmithKline Plc - Key news
• Exhibits139: GlaxoSmithKline Plc - Key offerings
• Exhibits140: GlaxoSmithKline Plc - Segment focus
• Exhibits141: Gwo Xi Stem Cell Applied Technology - Overview
• Exhibits142: Gwo Xi Stem Cell Applied Technology - Product / Service
• Exhibits143: Gwo Xi Stem Cell Applied Technology - Key offerings
• Exhibits144: Johnson and Johnson - Overview
• Exhibits145: Johnson and Johnson - Business segments
• Exhibits146: Johnson and Johnson - Key news
• Exhibits147: Johnson and Johnson - Key offerings
• Exhibits148: Johnson and Johnson - Segment focus
• Exhibits149: Kezar Life Sciences Inc. - Overview
• Exhibits150: Kezar Life Sciences Inc. - Product / Service
• Exhibits151: Kezar Life Sciences Inc. - Key news
• Exhibits152: Kezar Life Sciences Inc. - Key offerings
• Exhibits153: Merck KGaA - Overview
• Exhibits154: Merck KGaA - Business segments
• Exhibits155: Merck KGaA - Key news
• Exhibits156: Merck KGaA - Key offerings
• Exhibits157: Merck KGaA - Segment focus
• Exhibits158: Novartis AG - Overview
• Exhibits159: Novartis AG - Business segments
• Exhibits160: Novartis AG - Key offerings
• Exhibits161: Novartis AG - Segment focus
• Exhibits162: Novo Nordisk AS - Overview
• Exhibits163: Novo Nordisk AS - Business segments
• Exhibits164: Novo Nordisk AS - Key offerings
• Exhibits165: Novo Nordisk AS - Segment focus
• Exhibits166: Pfizer Inc. - Overview
• Exhibits167: Pfizer Inc. - Product / Service
• Exhibits168: Pfizer Inc. - Key news
• Exhibits169: Pfizer Inc. - Key offerings
• Exhibits170: Protagonist Therapeutics Inc. - Overview
• Exhibits171: Protagonist Therapeutics Inc. - Product / Service
• Exhibits172: Protagonist Therapeutics Inc. - Key offerings
• Exhibits173: Inclusions checklist
• Exhibits174: Exclusions checklist
• Exhibits175: Currency conversion rates for US$
• Exhibits176: Research methodology
• Exhibits177: Validation techniques employed for market sizing
• Exhibits178: Information sources
• Exhibits179: List of abbreviations

Abstract

The liver cirrhosis therapeutics market is forecasted to grow by USD 1.94 bn during 2023-2028, accelerating at a CAGR of 5.58% during the forecast period. The report on the liver cirrhosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of liver cancer, advancements in medical research, and increasing collaborations between pharmaceutical companies and healthcare providers.

Technavio's liver cirrhosis therapeutics market is segmented as below:

By Type

• Oral
• Injection

By End-user

• Hospitals
• Clinics
• Research and academic institutes

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the trend towards personalized medicine as one of the prime reasons driving the liver cirrhosis therapeutics market growth during the next few years. Also, increasing emphasis on non-invasive treatment options and integration of digital health technologies will lead to sizable demand in the market.

The report on the liver cirrhosis therapeutics market covers the following areas:

• Liver cirrhosis therapeutics market sizing
• Liver cirrhosis therapeutics market forecast
• Liver cirrhosis therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading liver cirrhosis therapeutics market vendors that include AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics. Also, the liver cirrhosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary - Chart on Market Segmentation by End-user
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global liver cirrhosis therapeutics market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global liver cirrhosis therapeutics market 2018 - 2022 ($ billion)
• 4.2 Type Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
• 4.3 End-user Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

• 6.1 Market segments
• Exhibit 30: Chart on Type - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
• 6.2 Comparison by Type
• Exhibit 32: Chart on Comparison by Type
• Exhibit 33: Data Table on Comparison by Type
• 6.3 Oral - Market size and forecast 2023-2028
• Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 6.4 Injection - Market size and forecast 2023-2028
• Exhibit 38: Chart on Injection - Market size and forecast 2023-2028 ($ billion)
• Exhibit 39: Data Table on Injection - Market size and forecast 2023-2028 ($ billion)
• Exhibit 40: Chart on Injection - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Injection - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Type
• Exhibit 42: Market opportunity by Type ($ billion)
• Exhibit 43: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by End-user

• 7.1 Market segments
• Exhibit 44: Chart on End-user - Market share 2023-2028 (%)
• Exhibit 45: Data Table on End-user - Market share 2023-2028 (%)
• 7.2 Comparison by End-user
• Exhibit 46: Chart on Comparison by End-user
• Exhibit 47: Data Table on Comparison by End-user
• 7.3 Hospitals - Market size and forecast 2023-2028
• Exhibit 48: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
• Exhibit 49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
• Exhibit 50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
• 7.4 Clinics - Market size and forecast 2023-2028
• Exhibit 52: Chart on Clinics - Market size and forecast 2023-2028 ($ billion)
• Exhibit 53: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion)
• Exhibit 54: Chart on Clinics - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Clinics - Year-over-year growth 2023-2028 (%)
• 7.5 Research and academic institutes - Market size and forecast 2023-2028
• Exhibit 56: Chart on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
• Exhibit 57: Data Table on Research and academic institutes - Market size and forecast 2023-2028 ($ billion)
• Exhibit 58: Chart on Research and academic institutes - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Research and academic institutes - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by End-user
• Exhibit 60: Market opportunity by End-user ($ billion)
• Exhibit 61: Data Table on Market opportunity by End-user ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 Japan - Market size and forecast 2023-2028
• Exhibit 95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibit 96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibit 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.11 China - Market size and forecast 2023-2028
• Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Alnylam Pharmaceuticals Inc.
• Exhibit 111: Alnylam Pharmaceuticals Inc. - Overview
• Exhibit 112: Alnylam Pharmaceuticals Inc. - Product / Service
• Exhibit 113: Alnylam Pharmaceuticals Inc. - Key news
• Exhibit 114: Alnylam Pharmaceuticals Inc. - Key offerings
• 12.4 Astellas Pharma Inc.
• Exhibit 115: Astellas Pharma Inc. - Overview
• Exhibit 116: Astellas Pharma Inc. - Product / Service
• Exhibit 117: Astellas Pharma Inc. - Key news
• Exhibit 118: Astellas Pharma Inc. - Key offerings
• 12.5 AstraZeneca Plc
• Exhibit 119: AstraZeneca Plc - Overview
• Exhibit 120: AstraZeneca Plc - Product / Service
• Exhibit 121: AstraZeneca Plc - Key news
• Exhibit 122: AstraZeneca Plc - Key offerings
• 12.6 CSL Ltd.
• Exhibit 123: CSL Ltd. - Overview
• Exhibit 124: CSL Ltd. - Business segments
• Exhibit 125: CSL Ltd. - Key offerings
• Exhibit 126: CSL Ltd. - Segment focus
• 12.7 F. Hoffmann La Roche Ltd.
• Exhibit 127: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 128: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 129: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 130: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 131: F. Hoffmann La Roche Ltd. - Segment focus
• 12.8 Gilead Sciences Inc.
• Exhibit 132: Gilead Sciences Inc. - Overview
• Exhibit 133: Gilead Sciences Inc. - Product / Service
• Exhibit 134: Gilead Sciences Inc. - Key news
• Exhibit 135: Gilead Sciences Inc. - Key offerings
• 12.9 GlaxoSmithKline Plc
• Exhibit 136: GlaxoSmithKline Plc - Overview
• Exhibit 137: GlaxoSmithKline Plc - Business segments
• Exhibit 138: GlaxoSmithKline Plc - Key news
• Exhibit 139: GlaxoSmithKline Plc - Key offerings
• Exhibit 140: GlaxoSmithKline Plc - Segment focus
• 12.10 Gwo Xi Stem Cell Applied Technology
• Exhibit 141: Gwo Xi Stem Cell Applied Technology - Overview
• Exhibit 142: Gwo Xi Stem Cell Applied Technology - Product / Service
• Exhibit 143: Gwo Xi Stem Cell Applied Technology - Key offerings
• 12.11 Johnson and Johnson
• Exhibit 144: Johnson and Johnson - Overview
• Exhibit 145: Johnson and Johnson - Business segments
• Exhibit 146: Johnson and Johnson - Key news
• Exhibit 147: Johnson and Johnson - Key offerings
• Exhibit 148: Johnson and Johnson - Segment focus
• 12.12 Kezar Life Sciences Inc.
• Exhibit 149: Kezar Life Sciences Inc. - Overview
• Exhibit 150: Kezar Life Sciences Inc. - Product / Service
• Exhibit 151: Kezar Life Sciences Inc. - Key news
• Exhibit 152: Kezar Life Sciences Inc. - Key offerings
• 12.13 Merck KGaA
• Exhibit 153: Merck KGaA - Overview
• Exhibit 154: Merck KGaA - Business segments
• Exhibit 155: Merck KGaA - Key news
• Exhibit 156: Merck KGaA - Key offerings
• Exhibit 157: Merck KGaA - Segment focus
• 12.14 Novartis AG
• Exhibit 158: Novartis AG - Overview
• Exhibit 159: Novartis AG - Business segments
• Exhibit 160: Novartis AG - Key offerings
• Exhibit 161: Novartis AG - Segment focus
• 12.15 Novo Nordisk AS
• Exhibit 162: Novo Nordisk AS - Overview
• Exhibit 163: Novo Nordisk AS - Business segments
• Exhibit 164: Novo Nordisk AS - Key offerings
• Exhibit 165: Novo Nordisk AS - Segment focus
• 12.16 Pfizer Inc.
• Exhibit 166: Pfizer Inc. - Overview
• Exhibit 167: Pfizer Inc. - Product / Service
• Exhibit 168: Pfizer Inc. - Key news
• Exhibit 169: Pfizer Inc. - Key offerings
• 12.17 Protagonist Therapeutics Inc.
• Exhibit 170: Protagonist Therapeutics Inc. - Overview
• Exhibit 171: Protagonist Therapeutics Inc. - Product / Service
• Exhibit 172: Protagonist Therapeutics Inc. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 173: Inclusions checklist
• Exhibit 174: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 175: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 176: Research methodology
• Exhibit 177: Validation techniques employed for market sizing
• Exhibit 178: Information sources
• 13.5 List of abbreviations
• Exhibit 179: List of abbreviations